The Exceptional Patient in Cancer Care

NCT ID: NCT00543153

Last Updated: 2012-07-30

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

13 participants

Study Classification

OBSERVATIONAL

Study Start Date

2007-08-31

Study Completion Date

2010-08-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The objectives of this study is to conduct a multicenter, dual country (United States and Israel), study examining the experience of patients with cancer that were considered by their physicians as having exceptional course of survival related to their specific disease state.

The primary aim of the study is to develop a detailed description of patients' experience of an exceptional disease course. The secondary aim is to define the content domain for assessment and measurement of exceptional disease course in patients with cancer and identify lessons learned from these exceptional patients that can be a base for future studies to benefit others.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The investigators of this study are exploring the experience of people with cancer who are considered by their physicians as having an exceptional course of disease - people who have defied the odds and remain well despite the severity of the original diagnosis.

Participation in this study is completely voluntary. Lessons learned from recorded experience(s) may be helpful to other patients and can be a basis for future studies that may benefit other patients.

To participate in this important study is simple and not time consuming. You will have only one face-to-face or telephone interview with a research assistant. During the interview you will simply be asked to describe your perspective, thoughts, and behaviors that you think are related to your disease course and lessons that you think others may gain benefit from. The interview will last about one hour and will be conducted at a time that is convenient for you.

If you agree to participate a research assistant will schedule a time for a recorded interview by phone or if possible at a location convenient to you. The interviews will be taped and transcribed. All recorded interviews will be retained for a minimum of 6 years.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Advanced Cancer

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

Advanced Cancer Exceptional Patient Cancer Care Interview

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_ONLY

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Patients diagnosed with cancer

Interview

Intervention Type BEHAVIORAL

Interview lasting approximately 30-45 minutes.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Interview

Interview lasting approximately 30-45 minutes.

Intervention Type BEHAVIORAL

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. 18 years of age or older
2. Ability to speak and read English with patients residing in the US, ability to speak and read Hebrew with patients residing in Israel.
3. Diagnosis of cancer confirmed by pathology.
4. Exceptional disease course as identified by patients' physician, in terms of survival and unusual disease course that is appropriately medically documented.
5. Consent to participate in this study.

Exclusion Criteria

1. Inability to understand the intent of the study.
2. Medical condition that would preclude participation in an interview session lasting 30-45 minutes.
3. Diagnosis of active psychosis or severe cognitive impairment confirmed by the patient's attending physician.
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

M.D. Anderson Cancer Center

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Moshe A. Frenkel, MD

Role: PRINCIPAL_INVESTIGATOR

M.D. Anderson Cancer Center

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

UT MD Anderson Cancer Center

Houston, Texas, United States

Site Status

Tel Aviv University

Tel Aviv, , Israel

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States Israel

References

Explore related publications, articles, or registry entries linked to this study.

Frenkel M, Ari SL, Engebretson J, Peterson N, Maimon Y, Cohen L, Kacen L. Activism among exceptional patients with cancer. Support Care Cancer. 2011 Aug;19(8):1125-32. doi: 10.1007/s00520-010-0918-6. Epub 2010 May 29.

Reference Type RESULT
PMID: 20512358 (View on PubMed)

Related Links

Access external resources that provide additional context or updates about the study.

http://www.mdanderson.org

The University of Texas M.D.Anderson Cancer Center

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

2007-0435

Identifier Type: -

Identifier Source: org_study_id